Predicting Progression to Mild Cognitive Impairment

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Despite much attention to the use of biomarkers for predicting Alzheimer disease, little information is available at the individual level. We used the population-based Mayo Clinic Study of Aging to estimate absolute risk of cognitive impairment by biomarker group. Risk increased with age and any biomarker abnormality. For example, a 75-year-old with abnormal amyloid and cortical thinning biomarkers has about a 20% chance of cognitive impairment by age 80 years, whereas with normal biomarkers the chance is <10%. Persons with only one abnormal biomarker had similar intermediate risks. ANN NEUROL 2019;85:155–160.

Original languageEnglish (US)
Pages (from-to)155-160
Number of pages6
JournalAnnals of neurology
Issue number1
StatePublished - Jan 2019

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Predicting Progression to Mild Cognitive Impairment'. Together they form a unique fingerprint.

Cite this